Logo image of NMRD

NEMAURA MEDICAL INC (NMRD) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:NMRD - US6404422080 - Common Stock

0.1053 USD
-0.02 (-17.8%)
Last: 1/4/2024, 8:15:19 PM
0.12 USD
+0.01 (+13.96%)
After Hours: 1/4/2024, 8:15:19 PM
Fundamental Rating

1

NMRD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 188 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NMRD have multiple concerns. NMRD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NMRD had negative earnings in the past year.
NMRD had a negative operating cash flow in the past year.
In the past 5 years NMRD always reported negative net income.
NMRD had a negative operating cash flow in each of the past 5 years.
NMRD Yearly Net Income VS EBIT VS OCF VS FCFNMRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5M -10M

1.2 Ratios

NMRD has a worse Return On Assets (-114.35%) than 86.00% of its industry peers.
Industry RankSector Rank
ROA -114.35%
ROE N/A
ROIC N/A
ROA(3y)-59.24%
ROA(5y)-122.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NMRD Yearly ROA, ROE, ROICNMRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K -2K 4K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for NMRD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NMRD Yearly Profit, Operating, Gross MarginsNMRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

NMRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NMRD has more shares outstanding
Compared to 5 years ago, NMRD has more shares outstanding
Compared to 1 year ago, NMRD has a worse debt to assets ratio.
NMRD Yearly Shares OutstandingNMRD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NMRD Yearly Total Debt VS Total AssetsNMRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

NMRD has an Altman-Z score of -12.89. This is a bad value and indicates that NMRD is not financially healthy and even has some risk of bankruptcy.
NMRD has a worse Altman-Z score (-12.89) than 83.00% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.89
ROIC/WACCN/A
WACC5.51%
NMRD Yearly LT Debt VS Equity VS FCFNMRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M

2.3 Liquidity

A Current Ratio of 0.38 indicates that NMRD may have some problems paying its short term obligations.
NMRD has a Current ratio of 0.38. This is amonst the worse of the industry: NMRD underperforms 96.50% of its industry peers.
NMRD has a Quick Ratio of 0.38. This is a bad value and indicates that NMRD is not financially healthy enough and could expect problems in meeting its short term obligations.
NMRD's Quick ratio of 0.24 is on the low side compared to the rest of the industry. NMRD is outperformed by 97.00% of its industry peers.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.24
NMRD Yearly Current Assets VS Current LiabilitesNMRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

3

3. Growth

3.1 Past

NMRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.06%, which is quite impressive.
Looking at the last year, NMRD shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)39.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, NMRD will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.37% on average per year.
Based on estimates for the next years, NMRD will show a very strong growth in Revenue. The Revenue will grow by 238.97% on average per year.
EPS Next Y42.95%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year43.63%
Revenue Next 2Y238.97%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

NMRD Yearly Revenue VS EstimatesNMRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 1M 2M 3M
NMRD Yearly EPS VS EstimatesNMRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -0.1 -0.2 -0.3 -0.4 -0.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NMRD. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NMRD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NMRD Price Earnings VS Forward Price EarningsNMRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NMRD Per share dataNMRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

A more expensive valuation may be justified as NMRD's earnings are expected to grow with 17.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.37%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NMRD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEMAURA MEDICAL INC

NASDAQ:NMRD (1/4/2024, 8:15:19 PM)

After market: 0.12 +0.01 (+13.96%)

0.1053

-0.02 (-17.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-13 2023-11-13/amc
Earnings (Next)02-22 2024-02-22/amc
Inst Owners0.14%
Inst Owner Change0%
Ins Owners120.13%
Ins Owner Change0%
Market Cap3.04M
Revenue(TTM)N/A
Net Income(TTM)-10.20M
Analysts82.86
Price Target8.67 (8133.62%)
Short Float %0%
Short Ratio0
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.31%
Min EPS beat(2)41.18%
Max EPS beat(2)55.44%
EPS beat(4)3
Avg EPS beat(4)37.05%
Min EPS beat(4)-10.29%
Max EPS beat(4)61.87%
EPS beat(8)5
Avg EPS beat(8)17.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-68.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)54.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)18.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-44.83%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS-0.55
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -114.35%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.24%
ROA(5y)-122.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.24
Altman-Z -12.89
F-Score1
WACC5.51%
ROIC/WACCN/A
Cap/Depr(3y)460.04%
Cap/Depr(5y)413.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
EPS Next Y42.95%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year43.63%
Revenue Next 2Y238.97%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.69%
OCF growth 3YN/A
OCF growth 5YN/A

NEMAURA MEDICAL INC / NMRD FAQ

Can you provide the ChartMill fundamental rating for NEMAURA MEDICAL INC?

ChartMill assigns a fundamental rating of 1 / 10 to NMRD.


What is the valuation status of NEMAURA MEDICAL INC (NMRD) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEMAURA MEDICAL INC (NMRD). This can be considered as Overvalued.


Can you provide the profitability details for NEMAURA MEDICAL INC?

NEMAURA MEDICAL INC (NMRD) has a profitability rating of 0 / 10.


Can you provide the financial health for NMRD stock?

The financial health rating of NEMAURA MEDICAL INC (NMRD) is 0 / 10.